Trulieve Reports Q1 2026 Financial Results

TALLAHASSEE – Trulieve Cannabis Corp. entered 2026 with a first quarter that presents two concurrent narratives – a retail operation contending with sustained pricing pressure, and a company whose federal tax obligations are, for the first time, beginning to reflect a more normalized business reality.

The multistate Cannabis operator disclosed Q1 2026 revenue of $286.8 million, representing an approximately 4% decline year-over-year, as softness in retail sales driven by price compression across its dispensary network was only partially offset by stronger wholesale performance. The result fell within the company’s own projections. Ahead of the quarter, management had indicated that revenue would decline in the low- to mid-single-digit range sequentially, attributing the anticipated softness to seasonal factors.

Trulieve’s effective tax rate declined to 87% from 258% recorded in the same period a year prior, following the company’s decision to cease applying IRC Section 280E for the 2026 taxable year – a direct result of medical Cannabis being rescheduled to Schedule III under the federal Controlled Substances Act. That structural shift was sufficient to convert what had consistently registered as a net loss into a marginal profit: the company reported net income of $2.3 million for the quarter, compared to a net loss of $33.8 million in Q1 2025.

The broader financial metrics held steady. Trulieve achieved a gross margin of 59%, with GAAP gross profit of $170 million. Adjusted EBITDA reached $100 million, equivalent to 35% of revenue. The company generated $56 million in operating cash flow and $42 million in free cash flow, closing the quarter with $353 million in cash on hand. On the operational side, the company completed a $60 million private placement of senior secured notes due in 2030, expanded its customer rewards program to one million members, and opened three additional Florida dispensaries in DeLand, Fort Myers, and Lake Wales. The company now operates 240 retail locations nationwide and maintains more than 4 million square feet of cultivation and processing space.

The federal rescheduling decision warrants separate consideration. On April 23, 2026, the Trump administration finalized the reclassification of medical Cannabis from Schedule I to Schedule III. Per the terms of the final order, Section 280E of the Internal Revenue Code no longer applies to Schedule III substances, effectively eliminating the tax provision that had long prohibited Cannabis companies from deducting standard business expenses. The order additionally established an expedited DEA registration pathway for state-licensed operators and created more defined conditions for clinical research utilizing state-available medical Cannabis products.

The financial impact of that policy change is already visible in Trulieve’s filings. The company’s provision for income taxes in Q1 2026 totaled $21.9 million, a reduction of $30.6 million from the $52.5 million recorded in Q1 2025, representing 12.9% of gross profit, compared to 28.6% in the prior-year period.

On the revenue front, retail pricing compression across the domestic Cannabis sector shows no definitive signs of stabilization. Management has guided for full-year 2026 operating cash flow of no less than $250 million, capital expenditures of up to $85 million, a minimum of five new store openings, and approximately 45 store refreshes across its existing footprint.

Trulieve’s Q1 is an early data point in what may prove to be a structural inflection; not in revenues, which remain compressed across the sector, but in how much of those revenues operators actually get to keep. The company posted a nominal profit this quarter largely because Washington finally moved. Whether that shift compounds into something durable for Trulieve, and for the broader U.S. Cannabis market, will show more clearly by the time Q2 numbers land.